Kymera Therapeutics, Inc.
KYMR
Pozycja w akcjach
#2184
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Cena akcji
$114.91
Kapitalizacja rynkowa
$9.45B
Zmiana (1 dzień)
1.28%
Zmiana (1 rok)
97.03%
Kraj
US
Handel Kymera Therapeutics, Inc. (KYMR)
Kategoria
Healthcare
Przychody dla Kymera Therapeutics, Inc. (KYMR)
Przychody w Jun 2026 TTM: $104.99M
Według najnowszych raportów finansowych Kymera Therapeutics, Inc., obecny przychód firmy (TTM) wynosi $104.99M. W roku 2023 firma osiągnęła przychód w wysokości $78.59M wzrost w porównaniu do przychodu z roku 2022, który wynosił $46.83M. Przychód to całkowita kwota dochodu generowana przez firmę ze sprzedaży towarów lub usług. W przeciwieństwie do zysku, nie są odliczane żadne koszty.
Historia przychodów firmy Kymera Therapeutics, Inc. od 2018 do 2026
Przychody na koniec każdego roku
| Rok | Przychody | Zmień |
|---|---|---|
| 2026 (TTM) | $104.99M | 123.04% |
| 2024 | $47.07M | -40.11% |
| 2023 | $78.59M | 67.84% |
| 2022 | $46.83M | -35.71% |
| 2021 | $72.83M | 114.00% |
| 2020 | $34.03M | 1,059.99% |
| 2019 | $2.93M | 0.00% |
| 2018 | 0.00 | 0.00% |
Przychody podobnych firm lub konkurentów
| Firma | Przychody | Różnica w przychodach | Kraj |
|---|---|---|---|
| $12.62B | 11,924.40% |
US
|
|
| $2.23B | 2,022.13% |
US
|
|
| $15.74B | 14,896.17% |
AU
|
|
| $6.02B | 5,635.16% |
NL
|
|
| - | - |
CH
|
